- Stocks
- Pharma & Healthcare
- Sai Life Sciences
Sai Life Sciences share price
NSE: SAILIFEPharma & HealthcareDiagnostics & Research
Sai Life Sciences at a glance
Sai Life Sciences (NSE: SAILIFE) closed at ₹1,396.80 on 22 Oct 2026, down 0.06% on the day. With a market capitalisation of ₹29,633 Cr, it ranks 270th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 85.1× trailing earnings, against a return on equity of 8.0% in FY25. Over the past year the share price has risen 63.2%. Its 52-week range is ₹783.85 (5 Feb 2026) to ₹1,697.00 (9 Sep 2026); the last close is 17.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹602 Cr (+3.9% year on year) and net profit ₹104 Cr (+18.1%), on a consolidated basis. Promoters held 34.53% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹29,633 CrRank 270 on NSE
- P/E (trailing)
- 85.1×
- Price to book
- 7.46×FY25
- EPS (TTM)
- ₹16.61to Q4 FY26
- ROE
- 8.0%FY25
- ROCE
- 12.5%FY25
- Debt to equity
- 0.06FY25
- Net profit margin
- 10.0%FY25
- Book value / share
- ₹102.12FY25
- 52-week high
- ₹1,697.009 Sep 2026
- 52-week low
- ₹783.855 Feb 2026
- 1-year return
- +63.2%
- RSI (14-day)
- 33.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.06% | −2.2% | −13.3% | +11.5% | +63.2% |
Sai Life Sciences quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹280 Cr | ₹396 Cr | ₹440 Cr | ₹580 Cr | ₹496 Cr | ₹537 Cr | ₹556 Cr | ₹602 Cr |
| Revenue YoY | — | — | +14.6% | +30.9% | +77.5% | +35.9% | +26.5% | +3.9% |
| Net profit | −₹14 Cr | ₹42 Cr | ₹54 Cr | ₹88 Cr | ₹60 Cr | ₹84 Cr | ₹100 Cr | ₹104 Cr |
| Net profit YoY | — | — | +36.0% | +57.3% | — | +102.0% | +86.4% | +18.1% |
| Net margin | −4.8% | 10.5% | 12.2% | 15.2% | 12.2% | 15.6% | 18.0% | 17.3% |
| EPS | −₹0.71 | ₹2.22 | ₹2.89 | ₹4.24 | ₹2.90 | ₹4.01 | ₹4.77 | ₹4.93 |
Sai Life Sciences financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹870 Cr | ₹1,217 Cr | ₹1,465 Cr | ₹1,695 Cr |
| Operating profit | ₹10 Cr | ₹16 Cr | ₹109 Cr | ₹228 Cr |
| Net profit | ₹6 Cr | ₹10 Cr | ₹83 Cr | ₹170 Cr |
| EPS (₹) | ₹0.00 | ₹1.00 | ₹5.00 | ₹9.00 |
| Cash from operations | ₹105 Cr | ₹219 Cr | ₹263 Cr | ₹314 Cr |
| Total debt | ₹297 Cr | ₹261 Cr | ₹277 Cr | ₹0 Cr |
| Shareholders' equity | ₹879 Cr | ₹888 Cr | ₹975 Cr | ₹2,128 Cr |
Sai Life Sciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 35.17% | 35.15% | 34.93% | 34.70% | 34.61% | 34.53% |
| Foreign institutions | 12.36% | 14.58% | 22.49% | 21.40% | 21.17% | 19.65% |
| Domestic institutions | 13.26% | 21.64% | 29.94% | 31.41% | 31.54% | 32.71% |
| Non-institutions | 39.21% | 28.64% | 12.64% | 12.49% | 12.68% | 13.11% |
Sai Life Sciences vs peers
The listed Pharma & Healthcare companies nearest to Sai Life Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,602 Cr | 42.4 | 17.8% |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,812 Cr | 145.1 | 18.7% |
| MEDANTAGlobal Health | ₹1,215.10 | −1.65% | −10.1% | ₹32,216 Cr | 58.9 | 14.0% |
| LALPATHLABDr. Lal Path Labs | ₹1,838.50 | +0.46% | +16.3% | ₹30,907 Cr | 58 | 20.1% |
| WOCKPHARMAWockhardt | ₹1,889.60 | +0.46% | +38.2% | ₹30,150 Cr | 144.8 | 4.3% |
| SAILIFESai Life Sciences | ₹1,396.80 | −0.06% | +63.2% | ₹29,633 Cr | 85.1 | 8.0% |
| KIMSKrishna Institute of Medical Sciences | ₹671.30 | +0.04% | −5.5% | ₹28,080 Cr | 111.9 | 18.0% |
Ask anything about Sai Life Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against SAILIFE's own history. Try: “Why has SAILIFE moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAILIFE over five years” · “Compare SAILIFE with NH on margins and valuation”
Frequently asked questions about Sai Life Sciences
What is the share price of Sai Life Sciences today?
Sai Life Sciences (NSE: SAILIFE) last closed at ₹1,396.80 on 22 Oct 2026. Its 52-week high is ₹1,697.00 and its 52-week low is ₹783.85.
What is the market cap of Sai Life Sciences?
Sai Life Sciences' market capitalisation is ₹29,633 Cr (₹29,633 Cr) at the 22 Oct 2026 close, ranking 270th among the NSE companies Pivot tracks.
What is the P/E ratio of Sai Life Sciences?
Sai Life Sciences trades at a trailing P/E of 85.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.
What is the ROE and ROCE of Sai Life Sciences?
Return on equity was 8.0% in FY25 and return on capital employed was 12.5% in FY25 (consolidated figures).
Is Sai Life Sciences a debt-free company?
No. Sai Life Sciences' debt-to-equity ratio was 0.06 in FY25, with total debt of ₹0 Cr.
What were Sai Life Sciences' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Sai Life Sciences reported revenue of ₹602 Cr, +3.9% year on year, and net profit of ₹104 Cr, +18.1% year on year.
How has Sai Life Sciences stock performed over the last year?
Sai Life Sciences' share price has risen 63.2% over the past year, +11.5% over three months and −13.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Sai Life Sciences?
As of 30 Jun 2026: promoters 34.53%, foreign institutions 19.65%, domestic institutions 32.71%, non-institutions 13.11%.
Who are Sai Life Sciences' competitors?
The listed Pharma & Healthcare companies closest to Sai Life Sciences by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Global Health, Dr. Lal Path Labs, Wockhardt and Krishna Institute of Medical Sciences.
Is Sai Life Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sai Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAILIFE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text